Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
National Vision Q3 Results Set to Focus on Traffic, UBS Says

National Vision Q3 Results Set to Focus on Traffic, UBS Says

MT newswireMT newswire2026/11/03 16:30
12:30 PM EST, 11/03/2026 (MT Newswires) -- National Vision (EYE) Q3 results will likely center on whether the firm can continue growing amid weakness in customer traffic, UBS said in a note Monday. The results are due Nov. 12. "The key debate heading into the print remains traffic," it said. Still, the note said focusing on customer traffic misses changes in the business, pointing to growth through higher-value clients, premium lenses, store segmentation, and product innovation. "We think National Vision Q3 results should provide another proof point that its earnings algorithm can work even before traffic fully recovers," the note said. The report said the temporary e-commerce disruption that weighed on Q2 results has been resolved, which should support stronger comparable sales growth in Q3. UBS has a buy rating and a $34 price target on National Vision. Price: 16.82, Change: -0.31, Percent Change: -1.81
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss